Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- ... | April 14, 2023